Post-operative pain relief in patients undergoing laparoscopic cholecystectomy under general anaesthesia
Phase 3
- Conditions
- Health Condition 1: K802- Calculus of gallbladder without cholecystitis
- Registration Number
- CTRI/2020/08/027342
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.ASA physical status I and II.
2.Elective laparoscopic cholecystectomy.
Exclusion Criteria
1.Acute cholecystitis.
2.Carcinoma Gall bladder.
3.Hypersensitivity to study drugs.
4.Pregnant females.
5.Bleeding disorders.
6.Opioid addicts.
7.Patient refusal to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of intraperitoneal instillation of ropivacaine and butorphanol versus ropivacaine and nalbuphine for post-operative pain relief in patients undergoing laparoscopic cholecystectomy under general anaesthesia.Timepoint: After extubation of patient till 24 hours.
- Secondary Outcome Measures
Name Time Method To compare the timing of first request and frequency of rescue analgesia.Timepoint: After extubation of patient till 24 hours.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do intraperitoneal ropivacaine-butorphanol and ropivacaine-nalbuphine combinations modulate opioid receptor pathways and local anesthetic mechanisms for post-laparoscopic cholecystectomy pain relief in K802 patients?
What is the comparative efficacy of CTRI/2020/08/027342 Sponsor A's intraperitoneal ropivacaine-butorphanol versus ropivacaine-nalbuphine for post-laparoscopic cholecystectomy pain management against standard-of-care analgesics?
Which inflammatory or pain sensitivity biomarkers correlate with response to intraperitoneal ropivacaine-butorphanol or ropivacaine-nalbuphine in K802 patients undergoing laparoscopic cholecystectomy?
What are the adverse event profiles and management strategies for intraperitoneal ropivacaine-butorphanol versus ropivacaine-nalbuphine in CTRI/2020/08/027342's Phase III laparoscopic cholecystectomy trial?
What are the alternative mu/kappa opioid receptor modulators or local anesthetic combinations being explored for post-laparoscopic cholecystectomy pain relief compared to CTRI/2020/08/027342's ropivacaine-butorphanol and ropivacaine-nalbuphine approaches?